LOUISVILLE, CO--(Marketwire - July 9, 2008) - GlobeImmune, Inc. announced today the signing of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) at the National Institutes of Health (NIH) to jointly develop products intended to treat a variety of cancers. GlobeImmune will utilize its proprietary Tarmogen® technology to develop multiple immunotherapy products expressing various cancer antigens provided by the NIH and the NIH will conduct and fund preclinical and early clinical development of the product candidates.

Dr. Jeffrey Schlom, Chief of the Laboratory of Tumor Immunology and Biology at the NCI, will be the principal investigator for these studies. CEA (carcinoembryonic antigen), the first cancer antigen to be evaluated in this collaboration, is over-expressed in a number of human cancers, including over 90% of gastrointestinal cancers (colorectal, pancreas), 70% of non-small cell lung cancers (NSCLC) and 50% of breast cancers. Dr. Schlom's group has already published two manuscripts from the NCI-GlobeImmune preclinical collaboration (Bernstein et al, Vaccine (2008) 26, 509-521; and Wansley et al, Clinical Cancer Research; July 1, 2008). Preclinical studies performed by Dr. Schlom's group may be translated into NCI-funded clinical programs with promising Tarmogen candidates.

"We are delighted to be working with Dr. Schlom and his colleagues at the National Cancer Institute," commented Dr. Timothy C. Rodell, CEO of GlobeImmune. "Their involvement will bring substantial expertise and resources to investigate the potential of our technologies with these important cancer targets. This collaboration has the potential to allow GlobeImmune to bring additional products into the clinic."

About GlobeImmune, Inc.

GlobeImmune is a private Colorado-based company developing active immunotherapies called Tarmogens for the treatment of cancer and infectious diseases. The Company's lead infectious disease product candidate, GI-5005, is being developed for the treatment of chronic hepatitis C infection. The Company has completed enrollment of a randomized phase 2 trial of GI-5005 in combination with the current standard of care. The Company's lead oncology product, GI-4000, is designed to be a treatment for cancers of the lung and gastrointestinal tract that are driven by mutations in the Ras oncogene product. A randomized, placebo-controlled phase 2 trial in patients with resectable pancreas cancer in combination with adjuvant gemcitabine is ongoing. Additionally, a phase 2 trial in non-small cell lung cancer is currently enrolling at Memorial Sloan Kettering Cancer Center. For additional information, please visit the company's website at www.globeimmune.com.

This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of clinical trial programs and potential advantages of the Company's technology and product candidates. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in this release.